Olema reports Q3 2026 results, reiterates early-2027 OPERA-01 data timelineNov 16Regulatory decisionOlema Pharmaceuticals, Inc.palazestrant
Prelude reports Q3 2026 results, advances KAT6A and JAK2V617F programsNov 16Quarterly updateLeonaBioPrelude Therapeutics Incorporated
FDA approves capivasertib combo for PTEN-deficient prostate cancerNov 6Regulatory decisionAstraZenecacapivasertib
Pfizer raises 2026 guidance after Q3, reports pipeline progress and new CFONov 3Quarterly updateBioNTech SEC4 Therapeutics, Inc.
Emergent BioSolutions cuts 2026 revenue and EBITDA guidance as Q3 sales fall 52%Nov 2Quarterly updateAmgenAprea Therapeutics
UIC registers Phase 1 trial of Pfizer's elranatamab in plasmablastic lymphomaOct 30Weekly roundup, 11 itemsAstellas Pharmaatirmociclib
Pfizer registers four studies: elranatamab, berobenatide, tilrekimig, and completed etrasimod trialOct 23Weekly roundup, 14 itemsabrocitinibatirmociclibUpdated
Roche adds Phase III trials in flu prophylaxis and diabetes, plus pediatric SMA study updateOct 22Weekly roundup, 6 itemsbaloxavir marboxilChugai PharmaceuticalUpdated
Genentech lists Phase Ib KRAS G12D trial; Roche-sponsored DLBCL study shows updateOct 9Weekly roundup, 9 itemsalectinibcisplatinUpdated
Loxo posts Phase 3 pirtobrutinib results; five more Lilly-linked trials updateSep 25Weekly roundup, 6 itemsabemaciclibbrenipatide
Tvardi's TTI-101 breast cancer trial posts results after early terminationSep 24Trial updateTTI-101Tvardi Therapeutics, Incorporated
Roche results post for two terminated Morpheus umbrella trials; new Phase 1/2 studies registeredAug 7Weekly roundup, 6 itemsatezolizumabBioLineRx, Ltd.
Relay Therapeutics files to sell up to $213 million more shares via TD CowenAug 6FinancingRelay Therapeutics, Inc.
Novartis posts BioItaLEE and China ribociclib results; registers three new studiesJul 10Weekly roundup, 5 itemsalpelisibinclisiran
Novartis: Mayzent label update approved; four real-world studies registered or recruitingJul 2Weekly roundup, 7 itemsalpelisibFludarabine